Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Kyorin to Transfer Pekiron to Galderma
October 11, 2012
- Sanofi Files Lawsuit against 3 Companies for Approved Allegra Generics
October 11, 2012
- Policy Directions Headed for “Price Cuts for Long-Listed Drugs,” “Price Control for High Priced Drugs”: Prof. Nakamura of Keio Univ.
October 11, 2012
- Lack of Patient Satisfaction with BPH Treatments Offers Opportunity; Can Kissei Get Them to Switch to Urief?
October 11, 2012
- Biz Entertainment Spending by MRs Falls at Most Companies, Down 80% at Foreign Firm: Jiho Poll
October 10, 2012
- Daiichi Sankyo Espha Considers Manufacturing Generics to Be Listed in 2014 at Ranbaxy’s Factory
October 10, 2012
- Chugai Files Avastin for Ovarian Cancer
October 10, 2012
- Ethical Drug Sales Down 1.4% in August: Crecon Report
October 10, 2012
- Companies Voice Concern over Implementation of Bar Code Labeling Due to Few Design Companies
October 9, 2012
- Zeria Terminates Development of Allergic Rhinitis Treatment
October 9, 2012
- Towa Consolidates Distribution Bases to 2 Sites in Eastern and Western Japan
October 9, 2012
- Takeda to Acquire LigoCyte of the US to Strengthen Vaccine Business
October 9, 2012
- Takeda Appeals to IP High Court in Actos Patent Lawsuit
October 9, 2012
- Ono, Carna Biosciences Conclude Capital Alliance Agreement, Making Ono Carna’s Largest Shareholder
October 9, 2012
- GSK’s Requip CR Tablets More Economical and Effective; Sales May Decrease despite Investment in Improved Formulation
October 8, 2012
- All Sawai MRs to Use iPads, First for Generics Maker
October 5, 2012
- Data Acquisition Completed for Anti-HIV Treatment, Submission for Regulatory Approval in US, Europe Planned By Year End: Shionogi
October 5, 2012
- Novartis to See Tasigna Sales More than Double, Value of Glivec Maximized
October 5, 2012
- Kyowa Kirin Files for Approval Based on Public Knowledge for IM Administration and Dosage for Leunase
October 5, 2012
- Ono Conducts Nation’s First Microdosing Study for New Drug Candidate
October 5, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…